BCR-ABL-IN-13 is a dual inhibitor of c-Src and Abl, exhibiting a Ki value of 0.55 μM against c-Src and 0.10 μM against wild-type Abl, with a Ki of 0.40 μM against the drug-resistant AblT315I mutant. This compound demonstrates competitive to mixed-type inhibition of wild-type Abl and non-competitive inhibition of the AblT315I mutant. BCR-ABL-IN-13 is suitable for research applications related to chronic myeloid leukemia, particularly in studies targeting resistant forms of the disease.
BCR-ABL-IN-13 is a dual inhibitor of c-Src and Abl, exhibiting a Ki value of 0.55 μM against c-Src and 0.10 μM against wild-type Abl, with a Ki of 0.40 μM against the drug-resistant AblT315I mutant. This compound demonstrates competitive to mixed-type inhibition of wild-type Abl and non-competitive inhibition of the AblT315I mutant. BCR-ABL-IN-13 is suitable for research applications related to chronic myeloid leukemia, particularly in studies targeting resistant forms of the disease.
This calculator helps you calculate mass of compound based on solution concentration, volume and molecular weight in a specific solution using the formula:
